The New York University School of Medicine has a long established record of training academic hematologists. In large part, this record has been fostered by the continuous support, since 1962, of a NIH Training Grant (T32) which supports 6 M.D., M.D., PhD, and PhD Trainees. The long term goal of the Training Program is to prepare Hematology Trainees for future careers in academic medicine. The interaction of both M.D., M.D./ PhD, and PhD Trainees in a unified Training Program serves to increase the number of physicians and scientists committed to a career in research. The Training Program exposes Trainees to rigorous mentored lab based hematology research, a detailed curriculum, seminar series, a journal club,a clinical management conference, and the opportunity to participate (for M.D Trainees) or observe (for PhD Trainees) the practice of clinical hematology relevant to the Trainee's laboratory investigation. Trainees are selected from the ACGME accredited adult and pediatric hematology/medical oncology fellowship programs and from eligible post- doctoral PhD fellows in participating faculty member's laboratories. The program, led by a Director with three well qualified Associate Directors, is specifically dedicated to actively recruiting underrepresented minorities. Our 15 Mentors have experience in mentoring and documented productivity, and their laboratories are highly interactive and use a variety of model systems to study 1) benign hematology including PNH, platelet biology and Fanconi anemia;2) the genetics of leukemia;3) JAK/STAT and Ras signaling mechanisms in hematopoietic stem cells, lymphopoieis, leukemia and lymphoma;4) lymphopoiesis and lymphocyte activation (including GVHD);5) mechanisms of myeloid and lymphoid trafficking;6) ubiquitination in hematopoietic stem cell biology, lymphopoiesis, and leukemia/lymphoma;and 7) the epigenetic and molecular basis of normal and abnormal hematopoiesis. Past graduates of our program have achieved the highest ranks of academia and have made lasting contributions to the field of hematology, and a high proportion of our recent graduates remain in academia, using the research skills gained as Trainees in careers as researchers, academic teachers and trialists. Over the last 10 years the majority of our graduates have obtained positions in academic institutions, have published their findings in the highest tier of journals, and have received multiple NIH and foundation awards.

Public Health Relevance

Hematological disorders represent a major cause of death in the U.S. Insights into many diseases have also come from laboratory-based research of hematological disorders and hematopoiesis. Well trained physicians and scientists will lead the way to new treatments for these disorders through fundamental and translational research, education, and clinical trials.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Institutional National Research Service Award (T32)
Project #
2T32HL007151-36
Application #
8607705
Study Section
NHLBI Institutional Training Mechanism Review Committee (NITM)
Program Officer
Chang, Henry
Project Start
1975-07-01
Project End
2019-06-30
Budget Start
2014-07-01
Budget End
2015-06-30
Support Year
36
Fiscal Year
2014
Total Cost
Indirect Cost
Name
New York University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
City
New York
State
NY
Country
United States
Zip Code
10016
Saint Fleur-Lominy, Shella; Maus, Mate; Vaeth, Martin et al. (2018) STIM1 and STIM2 Mediate Cancer-Induced Inflammation in T Cell Acute Lymphoblastic Leukemia. Cell Rep 24:3045-3060.e5
Cullis, Jane; Siolas, Despina; Avanzi, Antonina et al. (2017) Macropinocytosis of Nab-paclitaxel Drives Macrophage Activation in Pancreatic Cancer. Cancer Immunol Res 5:182-190
Sayin, Volkan I; LeBoeuf, Sarah E; Singh, Simranjit X et al. (2017) Activation of the NRF2 antioxidant program generates an imbalance in central carbon metabolism in cancer. Elife 6:
Fehrenbacher, Nicole; Tojal da Silva, Israel; Ramirez, Craig et al. (2017) The G protein-coupled receptor GPR31 promotes membrane association of KRAS. J Cell Biol 216:2329-2338
Strazza, Marianne; Azoulay-Alfaguter, Inbar; Peled, Michael et al. (2017) PLC?1 regulates SDF-1?-induced lymphocyte adhesion and migration to sites of inflammation. Proc Natl Acad Sci U S A 114:2693-2698
Pyzer, A R; Stroopinsky, D; Rosenblatt, J et al. (2017) MUC1 inhibition leads to decrease in PD-L1 levels via upregulation of miRNAs. Leukemia 31:2780-2790
Romero, Rodrigo; Sayin, Volkan I; Davidson, Shawn M et al. (2017) Keap1 loss promotes Kras-driven lung cancer and results in dependence on glutaminolysis. Nat Med 23:1362-1368
Bar-Natan, Michal; Stroopinsky, Dina; Luptakova, Katarina et al. (2017) Bone marrow stroma protects myeloma cells from cytotoxic damage via induction of the oncoprotein MUC1. Br J Haematol 176:929-938
Xiang, Michael; Kim, Haesook; Ho, Vincent T et al. (2016) Gene expression-based discovery of atovaquone as a STAT3 inhibitor and anticancer agent. Blood 128:1845-1853
Santori, Fabio R (2015) Nuclear hormone receptors put immunity on sterols. Eur J Immunol 45:2730-41

Showing the most recent 10 out of 45 publications